TY - JOUR T1 - Prevalence of heart disease in patients hospitalized for an acute exacerbation of COPD: Impact on clinical outcome. A 6 month follow-up study JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p547 AU - Silvia Fernandez Serrano AU - Dan Sanchez Berenguer AU - Jaume Oriol AU - Ludmila San Vicente AU - Nuria Galofre AU - Gemma Beltran AU - Montse Altimira AU - Lidia Ortega Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p547.abstract N2 - Aim: In order to analyze the prevalence of heart disease “HD” (known or not) in patients hospitalized due to an acute exacerbation of COPD, we carried out a prospective study.Material and methods: A total of 103 patients were prospectively included. Clinical course and outcome were analyzed during a 6-month follow-up.Assessment of mean length of stay, mortality and hospital readmission was made. ECG, Echocardiography and NTproBNP value were used for the cardiac evaluation.Results: 103 patients (71.83±9.3 years) were recruited, 81% of them with GOLD stage ≥ 3.Thirty-seven patients had a HD (a “newly” disease in 14): group FI. The COPD was alone in 63: group FII.The mean length of stay was 5.74±3.4 days and the in-hospital mortality rate was 2.9%. At 6-month follow-up: the mortality rate was 4.9% and the readmission rate 46.6% (35.5% of early readmission). Between readmitted cases, 56% were in GOLD stage 4.With regard to the cardiac evaluation, the phisical examination (yugular venous distention: 21.1% vs 4.6%, p=0.017; peripheral edema:31.6% vs 12.3%, p=0.022, pulmonary rales: 18.4% vs 2%, p=0.04), the ECG (28.9% vs 10.8%, p=0.030), the ecocardiography (LVEF < 50%: 23.7% vs 6.2%, p=0.014) and NT-proBNP (> 1200 pg/ml: 44.4% vs 13.3%, p=0.003) were more freqüent abnormal in the group FI than in the group FII.Conclusions: 1. The global prevalence of HD in our cohort of patients with an acute exacerbation of COPD was 37%.2. In this setting, physical examination, an abnormal ECG, an EF<50% and a NTproBNP value > 1200pg/mL, could help to identify patients with a probable HD.3. Fifty-six% of readmissions were patients in GOLD stage IV. ER -